• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Rises Over 300 Points; US Adds 223,000 Jobs In December

    1/6/23 10:27:14 AM ET
    $AEHR
    $ATAI
    $DCP
    $FATE
    Electrical Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEHR alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday.

    Following the market opening Friday, the Dow traded up 1.02% to 33,265.17 while the NASDAQ rose 0.72% to 10,379.71. The S&P 500 also rose, gaining, 1.03% to 3,847.29.

    Check This Out: 5 Tech Stocks That Are Flying - And May Collapse


    Leading and Lagging Sectors


    Energy shares gained by 2.2% on Friday. Meanwhile, top gainers in the sector included HighPeak Energy, Inc. (NASDAQ:HPK), up 10%, and DCP Midstream, LP (NYSE:DCP), up 6%.


    In trading on Friday, health care shares dropped by 0.1%.


    Top Headline


    The US economy added 223,000 jobs in December, the least since December 2020, following a revised 256,000 increase in November, and above market estimates of 200,000.


    The unemployment rate fell to 3.5% in December. Average hourly earnings climbed 0.3% to $32.82 in December.

     

    Equities Trading UP

     

    • Aehr Test Systems (NASDAQ:AEHR) shares shot up 35% to $23.26 after the company reported better-than-expected Q2 EPS and sales results and announced it receieved a follow-on production order from its second major silicon carbide semiconductor customer for an additional production FOX-XP multi-wafer test and burn-in system configured with Aehr's fully integrated and automated WaferPak Aligner.
    • Shares of Sight Sciences, Inc. (NASDAQ:SGHT) got a boost, shooting 26% to $14.90. Stifel upgraded Sight Sciences from Hold to Buy and raised the price target from $10 to $15.
    • Immunome, Inc. (NASDAQ:IMNM) shares were also up, gaining 14% to $5.35 after the company and AbbVie announced a strategic collaboration to discover multiple novel oncology targets. Immunome will receive a $30 million upfront payment with the potential for milestones and royalties.

     

    Equities Trading DOWN

    • Fate Therapeutics, Inc. (NASDAQ:FATE) shares tumbled 63% to $4.11 after the company announced termination of its collaboration agreement with Janssen, pipeline prioritization, next-generation programs and key 2023 initiatives.
    • Shares of Graphite Bio, Inc. (NASDAQ:GRPH) were down 43% to $1.7550 after the company reported it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel.
    • Atai Life Sciences N.V. (NASDAQ:ATAI) was down, falling 39% to $1.6015 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.


    Also Check This Out: Bitcoin Remains Stable; Huobi Token, Aptos Among Top Losers


    Commodities

    In commodity news, oil traded up 1.5% to $74.77 while gold traded up 1.3% at $1,864.40.


    Silver traded down 2.2% to $23.94 on Friday while copper rose 1% to $3.86.

     



    Euro zone


    European shares were higher today. The eurozone’s STOXX 600 gained 0.6%, London’s FTSE 100 gained 0.6% while Spain’s IBEX 35 Index rose 0.7%. The German DAX gained 0.3%, French CAC 40 climbed 0.6% and Italy’s FTSE MIB Index gained 0.8%.


    Annual inflation rate in the Eurozone eased to 9.2% in December, the lowest in four months, while retail sales rose by 0.8% from a month ago in November.


    The S&P Global/CIPS UK construction PMI fell to 48.8 in December from 50.4 in the prior month, while the Halifax house price index rose 2% year-over-year in December versus a 4.6% increase a month ago. Factory orders in Germany fell 5.3% month-over-month in November, while retail sales in the country rose 1.1% month-over-month in November.

     


    Asia Pacific Markets


    Asian markets closed mixed on Friday, with the Hong Kong’s Hang Seng Index dropping 0.29%, and China’s Shanghai Composite Index adding 0.08%. Japan’s Nikkei 225 rose 0.59% during the session.


    Foreign exchange reserves in Hong Kong rose to $424 billion in December, the highest since August. The au Jibun Bank Japan Services PMI rose to 51.1 in December compared to a final reading of 50.3 in November, while average cash earnings in the country rose by 0.5% year-over-year in November.

     

    Economics

     

    • The US economy added 223,000 jobs in December, the least since December 2020, following a revised 256,000 increase in November, and above market estimates of 200,000.
    • The unemployment rate fell to 3.5% in December.
    • Average hourly earnings climbed 0.3% to $32.82 in December.
    • The ISM Services PMI declined to 49.6 in December, signalling the first contraction in the services activity since May 2020.
    • US factory orders fell by 1.8% in November.

     

    Now Read This: Why Fear Level Among US Investors Is Decreasing


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 103,048,880 cases with around 1,120,800 deaths. India confirmed a total of at least 44,680,600 cases and 530,700 deaths, while France reported over 39,381,820 COVID-19 cases with 162,640 deaths. In total, there were at least 667,484,690 cases of COVID-19 worldwide with more than 6,707,270 deaths.

    Get the next $AEHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEHR
    $ATAI
    $DCP
    $FATE

    CompanyDatePrice TargetRatingAnalyst
    Immunome Inc.
    $IMNM
    2/12/2026$40.00Buy
    H.C. Wainwright
    AtaiBeckley Inc.
    $ATAI
    1/20/2026$11.00Buy
    Guggenheim
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Aehr Test Systems
    $AEHR
    12/17/2025$29.00Buy
    Lake Street
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    Fate Therapeutics Inc.
    $FATE
    10/31/2025$5.00Neutral → Buy
    H.C. Wainwright
    Fate Therapeutics Inc.
    $FATE
    10/27/2025$7.00Neutral → Outperform
    Wedbush
    HighPeak Energy Inc.
    $HPK
    10/14/2025$12.00Buy
    Roth Capital
    More analyst ratings

    $AEHR
    $ATAI
    $DCP
    $FATE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtaiBeckley To Host Virtual Investor Day on March 6, 2026

    NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company's executive leadership team and several external key opinion leaders. Investors, analysts, and members of the media are invited to register for the live webcast. A replay will be made available following the event on the investor

    2/20/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast

    2/18/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

    SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)

    2/17/26 4:15:47 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sight Sciences Inc.

    SCHEDULE 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    2/4/26 12:09:03 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    2/3/26 5:30:15 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $149,053 worth of shares (7,278 units at $20.48) and gifted 200,000 shares, decreasing direct ownership by 23% to 660,525 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:38:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Tsai Philip bought $204,900 worth of shares (10,000 units at $20.49), increasing direct ownership by 30% to 43,300 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:32:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Immunome with a new price target

    H.C. Wainwright initiated coverage of Immunome with a rating of Buy and set a new price target of $40.00

    2/12/26 7:24:43 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on AtaiBeckley with a new price target

    Guggenheim initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $11.00

    1/20/26 9:22:21 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posedel Rhea J sold $420,151 worth of shares (13,998 units at $30.02) (SEC Form 4)

    4 - AEHR TEST SYSTEMS (0001040470) (Issuer)

    2/13/26 4:48:48 PM ET
    $AEHR
    Electrical Products
    Industrials

    VP Contactor Business Unit Sporck Alistair N sold $82,716 worth of shares (3,000 units at $27.57), decreasing direct ownership by 11% to 25,153 units (SEC Form 4)

    4 - AEHR TEST SYSTEMS (0001040470) (Issuer)

    2/10/26 4:17:52 PM ET
    $AEHR
    Electrical Products
    Industrials

    Chief Technology Officer Badawi David was granted 64,915 shares, increasing direct ownership by 3% to 1,977,188 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/5/26 4:49:56 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    Leadership Updates

    Live Leadership Updates

    View All

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

    SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experience in the life sciences industry, including over 10 years serving as CFO across innovative life science companies, with deep domain expertise in autoimmune diseases, including lupus. "We are excited to wel

    10/14/25 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    11/14/24 7:50:18 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 1:28:33 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEHR
    $ATAI
    $DCP
    $FATE
    Financials

    Live finance-specific insights

    View All

    Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast

    2/18/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacest

    12/15/25 7:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Presentation Slides and Conference Call Information Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to disc

    12/14/25 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care